Z
8.43
-0.17 (-1.98%)
| Penutupan Terdahulu | 8.60 |
| Buka | 8.71 |
| Jumlah Dagangan | 519,791 |
| Purata Dagangan (3B) | 1,903,985 |
| Modal Pasaran | 474,588,256 |
| Harga / Pendapatan (P/E TTM) | 17.94 |
| Harga / Pendapatan (P/E Ke hadapan) | 14.01 |
| Harga / Jualan (P/S) | 5.53 |
| Harga / Buku (P/B) | 3.52 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 5 Nov 2025 |
| Margin Keuntungan | -226.64% |
| Margin Operasi (TTM) | -26.28% |
| EPS Cair (TTM) | -1.94 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 495.70% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 150.74% |
| Nisbah Semasa (MRQ) | 3.02 |
| Aliran Tunai Operasi (OCF TTM) | -61.72 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -39.23 M |
| Pulangan Atas Aset (ROA TTM) | -27.73% |
| Pulangan Atas Ekuiti (ROE TTM) | -204.78% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Bercampur |
| Biotechnology (Global) | Bercampur | Bercampur | |
| Stok | Zevra Therapeutics, Inc. | Menurun | Menaik |
AISkor Stockmoo
0.0
| Konsensus Penganalisis | 1.5 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -2.0 |
| Purata Bergerak Teknikal | 1.0 |
| Osilator Teknikal | -0.5 |
| Purata | 0.00 |
|
Zevra Therapeutics Inc is a rare disease company combining science, data, and patient needs to create transformational therapies for diseases with limited or no treatment options. The company's mission is to bring life-changing therapeutics to people living with rare diseases. With data-driven development and commercialization strategies, it is overcoming complex drug development challenges to make new therapies available to the rare disease community. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Core |
| % Dimiliki oleh Orang Dalam | 0.69% |
| % Dimiliki oleh Institusi | 65.42% |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 24.00 (Cantor Fitzgerald, 184.70%) | Beli |
| 24.00 (Canaccord Genuity, 184.70%) | Beli | |
| Median | 24.00 (184.70%) | |
| Purata | 24.00 (184.70%) | |
| Jumlah | 2 Beli | |
| Harga Purata @ Panggilan | 9.09 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Canaccord Genuity | 06 Nov 2025 | 24.00 (184.70%) | Beli | 9.09 |
| Cantor Fitzgerald | 06 Nov 2025 | 24.00 (184.70%) | Beli | 9.09 |
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 02 Dec 2025 | Pengumuman | Zevra Therapeutics, Inc. Appoints Alicia Secor to Board of Directors; Announces Retirement of Wendy Dixon, PhD |
| 20 Nov 2025 | Pengumuman | Zevra Therapeutics, Inc. Announces CFO Transition |
| 05 Nov 2025 | Pengumuman | Zevra Reports Third Quarter 2025 Financial Results and Corporate Update |
| 29 Oct 2025 | Pengumuman | Zevra Therapeutics to Participate in the Guggenheim Healthcare Innovation Conference |
| 27 Oct 2025 | Pengumuman | Zevra Therapeutics Announces Details for Q3 2025 Financial Results Call |
| 06 Oct 2025 | Pengumuman | Zevra Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) |
| 18 Sep 2025 | Pengumuman | Zevra Therapeutics Announces Upcoming Oral Presentation at the International Niemann-Pick Disease Alliance (INPDA) Meeting and Poster Presentations at the Child Neurology Society (CNS) Conference on MIPLYFFA® (arimoclomol) and OLPRUVA® (sodium phenylb... |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |